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Porcine reproductive and respiratory syndrome virus (PRRSV) contains the major glycoprotein, GP5, as well
as three other minor glycoproteins, namely, GP2a, GP3, and GP4, on the virion envelope, all of which are
required for generation of infectious virions. To study their interactions with each other and with the cellular
receptor for PRRSV, we have cloned each of the viral glycoproteins and CD163 receptor in expression vectors
and examined their expression and interaction with each other in transfected cells by coimmunoprecipitation
(co-IP) assay using monospecific antibodies. Our results show that a strong interaction exists between the GP4
and GP5 proteins, although weak interactions among the other minor envelope glycoproteins and GP5 have
been detected. Both GP2a and GP4 proteins were found to interact with all the other GPs, resulting in the
formation of multiprotein complex. Our results further show that the GP2a and GP4 proteins also specifically
interact with the CD163 molecule. The carboxy-terminal 223 residues of the CD163 molecule are not required
for interactions with either the GP2a or the GP4 protein, although these residues are required for conferring
susceptibility to PRRSV infection in BHK-21 cells. Overall, we conclude that the GP4 protein is critical for
mediating interglycoprotein interactions and, along with GP2a, serves as the viral attachment protein that is
responsible for mediating interactions with CD163 for virus entry into susceptible host cell.
that are processed by different viral proteases encoded in the
ORF1a region to generate a total 13 or 14 nonstructural proteins (Nsp) named Nsp1␣, Nsp1␤, Nsp2 to -6, Nsp7␣, Nsp7␤,
and Nsp8 to -12 (29, 36, 47). The Nsps are involved in processing of the viral polyproteins, genome replication, and transcription (36). ORFs 2a, 2b, and 3 to 7 encompass approximately 25% of the genome at the 3⬘ end, and they produce the
viral structural proteins, namely, glycoprotein 2a (GP2a), nonglycosylated protein 2b (or E), GP3, GP4, GP5, the matrix
protein (M), and the nucleocapsid protein (N), respectively
(54). Of the structural proteins, GP2a, GP3, GP4, and GP5 are
N glycosylated and are present on the viral envelope (9), as are
the nonglycosylated M protein and 2b proteins. The M and
GP5 proteins are known to form heterodimers (35). The 2b (or
E) protein possesses ion-channel-like properties and may function as a viroporin on the envelope (30). GP5 is the most
abundant glycoprotein found on the surface of the virion and
hence is named the major envelope glycoprotein, whereas the
GP2a, GP3, and GP4 proteins, which are also present on
the surface of the virion in less abundant quantities, are termed
the minor envelope glycoproteins. Although early studies reported that the GP3 protein is not a structural component of
the North American (genotype II) PRRS virions (24, 34), recent studies from our laboratory have shown that it is present
on the virion envelope (10), an observation consistent with the
European (genotype I) PRRS virions (49). All of the major
and minor envelope proteins are required for generation of
infectious PRRSV (53). Previous studies with both PRRSV
and EAV have shown that the minor envelope glycoproteins
GP2a, GP3, and GP4 and the unglycosylated 2b protein form
a heterotetrameric complex in infected cells and that forma-

Porcine reproductive and respiratory syndrome virus
(PRRSV) is endemic in pork-producing countries worldwide.
Infection of pigs with the virus can result in PRRS disease,
leading to significant economic losses to the swine industry.
PRRSV causes respiratory disorders leading to pneumonia
and is responsible for mortality observed in young piglets. The
virus also infects pregnant sows, causing several reproductive
disorders resulting in abortion, infertility, mummified fetuses,
stillborn piglets, etc. PRRSV, along with equine arteritis virus
(EAV), simian hemorrhagic fever virus (SHFV), and lactate
dehydrogenase-elevating virus (LDV), is grouped in the family
Arteriviridae and the order Nidovirales (43) based on their similar genome organization and replication strategy. PRRSV is
classified into two genotypes, genotype I (European genotype)
and genotype II (North American genotype). These two genotypes share approximately 60% genome sequence homology
(20, 25).
The genome of PRRSV is approximately 15.4 kb in length.
It has nine open reading frames (ORFs). ORF 1a and ORF
1ab, which is accessed by ribosomal frameshifting during protein synthesis (43), together span approximately 75% of the
genome from the 5⬘ end. These ORFs produce polyproteins
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tion of such a complex is required for the transport of these
proteins from the endoplasmic reticulum (ER) to the Golgi
apparatus in infected cells prior to virion assembly (52, 53).
Furthermore, the GP5 and M proteins of EAV and the homologous proteins of LDV have been shown to form a heterodimer through disulfide bonds, which is required for viral
infectivity (2, 19, 42, 43). This heterodimeric GP5-M protein
interaction is required for proper posttranslational processing
of the proteins, and the N-linked glycosylation of GP5 is not
required for GP5-M heterodimer formation (35). Although the
envelope glycoproteins have been shown to form multimeric
complexes, the specific interactions among these glycoproteins
and how such interactions result in formation of the large
multimeric complex are currently unknown.
PRRSV has tropism for porcine alveolar macrophage
(PAM) cells, and sialoadhesin expressed on the surface of
these cells has been shown to be a receptor for PRRSV (12–
14). Under in vitro infection conditions, PRRSV has been
found to infect and replicate to high levels only in MARC-145
cells (27), a derivative of African green monkey kidney cell line
MA-104. However, the MARC-145 cells do not express sialoadhesin, indicating that molecules other than sialoadhesin
are involved in entry of PRRSV in MARC-145 cells. Although
several other molecules, such as vimentin, CD151, and heparin
sulfate, have been identified as potential entry molecules for
PRRSV (28, 41), recently porcine CD163 isolated from PAM
cells was found to confer susceptibility to PRRSV infection to
nonpermissive cells (5). Additionally, CD163 is also expressed
in MARC-145 cells, suggesting that it may be responsible for
entry of PRRSV in these cells. The GPs on the virion envelope
must then interact with CD163 to mediate virus entry into
these cells. At this time, it is unknown which of the viral
envelope glycoproteins directly interact with CD163 to mediate virus entry into susceptible cells. Since GP5 protein is
present on the PRRSV envelope in abundant amounts, it was
presumed to play an important role in interacting with the cell
surface receptor for PRRSV entry. However, studies in which
the ectodomains of the GP5 and M proteins of EAV were
replaced with the ectodomains of the corresponding proteins
from PRRSV or LDV in an EAV infectious clone, the resulting chimeric EAV did not exhibit the altered tissue tropism,
indicating that the GP5 protein may not be the PRRSV envelope protein that interacts with the receptor (17, 50). This
finding is suggestive of the involvement of other PRRSV envelope glycoproteins, especially the minor envelope glycoproteins of PRRSV, in receptor interaction and virus entry. However, to date, the PRRSV glycoprotein(s) that interacts with
the receptor CD163 has not been identified.
In this report, we have described studies to delineate the
interactions among the four envelope glycoproteins of PRRSV
as well as their interactions with the porcine CD163 receptor.
Our results have revealed that a strong interaction exists between the GP4 and GP5 proteins, although weak interactions
among the other glycoproteins have also been demonstrated.
In addition, we have observed that only GP2a and GP4 proteins interact with CD163. A truncated CD163 molecule lacking 223 amino acid (aa) residues from its carboxy terminus was
also found to interact with these two glycoproteins, indicating
that the carboxy-terminal residues of CD163 are not involved
in interactions with the GP2a or GP4 proteins.

J. VIROL.
MATERIALS AND METHODS
Cell culture, viruses, and reagents. Baby hamster kidney-21 (BHK-21) cells
were maintained in minimal essential medium (MEM) containing 5% fetal
bovine serum (FBS) and 100 units of penicillin, 20 units of kanamycin, and 20
units of streptomycin (PKS) antibiotics per milliliter of medium. MARC-145
cells were maintained as described before (1, 46). vTF7-3 virus (21), a recombinant vaccinia virus that expresses the bacteriophage T7 RNA polymerase in the
cytoplasm of infected cells, was grown and titrated in BHK-21 cells as described
before (1) and stored at ⫺80°C in small aliquots. The infectious clone-derived
FL-12 virus was grown in MARC-145 cells as described before (1, 46). Endoglycosidase H (endo H) was purchased from New England Biolabs (NEB) and used
at concentrations described earlier (1, 46). Protein molecular mass markers were
purchased from Bio-Rad.
Antibodies. The porcine anti-CD163 monoclonal antibody was purchased from
AbD Serotec USA (Raleigh, NC). The monoclonal antibody (SDOW17) against
the PRRSV nucleocapsid (38) was purchased from National Veterinary Services
Laboratories (Ames, IA). The anti-GP5 rabbit polyclonal antibody was kindly
provided by Carl Gagnon (University of Quebec, Montreal, Canada). Alexa
Fluor-488 goat anti-rabbit and anti-mouse immunoglobulin G (IgG) antibodies
were purchased from Molecular Probes and used as secondary antibodies for
fluorescence microscopy. Monospecific antibodies against GP2a, GP3, and GP4
were generated by coimmunization of rabbits with two highly immunogenic
peptides for each protein as described previously (10). The details of production
and characterization of the GP3 monospecific antibody were reported earlier
(10). The selection of peptides, their synthesis, and production of anti-GP2a and
anti-GP4 monospecific polyclonal antibodies were done by methods similar to
those reported previously (10, 11). The amino acid residues of the selected
peptides for GP2a are CEMVSRRMYRTMEKA and CKAGQAAWKQVVS
EAT. The amino acid residues of the selected peptides for GP4 are CLFYASE
MSEKGFK and CFTSYVQHVKEFTQR. The peptides were synthesized and
conjugated to a carrier protein (keyhole limpet hemocyanin [KLH]) either by
adding a cysteine residue at the amino terminus (underlined) or via activated
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) chemistry
to its N-terminal region. The antibodies were produced by Sigma and were
characterized in our laboratory. Sera collected at day 77 postimmunization were
used in all experiments.
Plasmid construction. The coding regions of the minor GPs were cloned from
the infectious clone FL-12 of PRRSV (46). The genes for the individual minor
GPs were amplified by PCR using gene-specific primers (Table 1) and cloned in
pGEM3 vector (Promega Biotech, Madison, WI) under the control of the T7
RNA polymerase promoter or in pcDNA3.1(⫹) vector (Invitrogen) under the
control of the cytomegalovirus (CMV) promoter and T7 RNA polymerase promoter. The FLAG tag (DYKDDDDK) was fused at the carboxy terminus of
GP2a by PCR using primers GP2a-FLAG-EcoRI-Rev and GP2a-NheI-For and
cloned in pGEM3 vector that was modified to contain the CMV promoter in
addition to the T7 RNA polymerase promoter. The ORF for GP3 and GP4 was
PCR amplified and cloned in pGEM3 vector by use of EcoRI and BamHI
restriction sites. The GP5 ORF was cloned in pGEM3 by use of EcoRI and
HindIII restriction sites. The nucleotide sequences of the plasmids encoding
various GPs were determined to ensure that the correct clones were used in the
studies.
The ORF of the porcine CD163 receptor was amplified from the total RNA
isolated from PAM cells by reverse transcription-PCR (RT-PCR) using specific
primers (Table 1) and cloned in pGEM-T vector (Promega Corporation). Four
clones of the CD163 receptor with inserts of the correct size were further
transferred from the pGEM-T vector by restriction enzyme digestion with
HindIII and XhoI and cloned by blunt-end ligation in pcDNA3.1(⫹) vector.
Transfection. Plasmids were transfected into cells using Lipofectamine 2000
(Invitrogen) as described earlier (1). Briefly, BHK-21 cells were plated in six-well
culture dishes at 24 h before transfection. The cells were first infected with
vTF7-3 (21) at a multiplicity of infection (MOI) of 5. The DNA-Lipofectamine
2000 complexes prepared according to the manufacturer’s recommendations
were added to the infected and washed BHK-21 cells and incubated at 37°C for
4 h. Following incubation, the cells were washed and incubated in Dulbecco’s
modified Eagle’s medium (DMEM) containing 2% FBS and antibiotics as described before (1). The transfected cells were processed for radiolabeling or
immunofluorescent staining as described below.
Metabolic labeling, IP, co-IP, and analysis of proteins. The plasmid-transfected cells at 16 to 18 h posttransfection were washed twice in phosphatebuffered saline (PBS) and incubated with cysteine-methionine-free DMEM for
1 h prior to radiolabeling with 33 Ci of Expre35S35S protein labeling mix
(Perkin-Elmer) per ml of methionine-cysteine-free DMEM without serum for
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TABLE 1. Primers used in this study
Nucleotide sequencea

Primer

GP2a-EcoRI-For .......................................................................ATATATGAATTCGCCACCATGAAATGGGGTCCATGC
GP2a-SphI-Rev..........................................................................ATATATGCATGCTCACCGTGAGTTCGAAGG
GP2a-NheI-For..........................................................................ATATGCTAGCGCCGCCACCATGAAATGGGGTCCATGC
GP2a-FLAG-EcoRI-Rev..........................................................ATATGAATTCTCACTCGAGCTTGTCATCGTCGTCCTTGTAGTCCATCCGTG
AGTTCGAAGGAAAAATTGC
GP3-EcoRI-For .........................................................................ATATAGAATTCGCCACCATGGCTAATAGCTGTGC
GP3-BamHI-Rev .......................................................................TATATGGATCCCTATCGCCGCGCGGC
GP4-EcoRI-For .........................................................................ATATAGAATTCGCCACCATGGCTGCGCCCCTTC
GP4-BamHI-Rev .......................................................................TATATGGATCCTCAAATTGCCAGTAAGATG
GP5-EcoRI-For .........................................................................GCCGGAATTCGGAGCCGCCGCCACCATGTTGGGGAGATGCTTGAC
GP5-HindIII-XhoI-Rev ............................................................ATCACTCGAGAAGCTTCTAAAGACGACCCCATTGTTC
CD163-HindIII-For...................................................................ATATAAGCTTATGGACAAACTCAGAATGGTGCTAC
CD163-XhoI-Rev ......................................................................ATATCTCGAGTCATTGTACTTCAGAGTGGTCTCCTG
a

Primer sequences are in the 5⬘ to 3⬘ direction. Restriction enzyme sites in the primers are underlined.

4 h. Following radiolabeling, the cells were washed with cold PBS and the cell
lysate was prepared in radioimmunoprecipitation assay (RIPA) buffer as described before (1) or in coimmunoprecipitation (co-IP) buffer (1% NP-40, 0.5%
Triton X-100, 50 mM Tris-HCl [pH 7.6], 500 mM NaCl, 2 mM EDTA, and 1⫻
protease inhibitor cocktail) as described before (8). The cell lysate was clarified
by centrifugation at 16,000 ⫻ g for 5 min. The supernatant was used for immunoprecipitation with the appropriate antibody at 4°C for 8 to 10 h. A slurry of
approximately 3.0 mg of protein A-Sepharose (GE Healthcare Bioscience AB)
washed and resuspended in 100 l RIPA buffer was added and incubated further
for 2 h at 4°C. The protein A-Sepharose beads with bound immune complexes
were washed in RIPA buffer or co-IP buffer three times, resuspended in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer
(50 mM Tris-HCl [pH 6.8], 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol
blue, and 10% glycerol), and boiled for 5 min. After centrifugation at 16,000 ⫻
g for 1 min, the proteins in the clarified supernatant were resolved by SDS-10%
or -12% PAGE. Following electrophoresis, the gels were processed for fluorography as described previously (1). Endo H treatment of immunoprecipitated
proteins was as described before (1).
Fluorescence microscopy. The transfected cells were fixed either with 4%
paraformaldehyde for 30 min at room temperature or with methanol-acetone
solution (1:1) for 30 min at ⫺20°C. The cells were blocked with 5% bovine serum
albumin (BSA) in PBS containing 0.05% Tween20 for 30 min at room temperature, and immunofluorescence staining was performed with appropriate primary and secondary antibodies as described previously (6, 7) and visualized
under an Olympus FV500/IX81 inverted laser scanning confocal microscope.
The images were captured with a charge-coupled-device camera.

RESULTS
Expression of PRRSV minor glycoproteins in transfected
cells. The minor glycoproteins GP2a, GP3, and GP4 of
PRRSV are 256 amino acids (aa), 254 aa, and 178 aa long,
respectively. The unglycosylated forms of these proteins have
predicted sizes of approximately 29 kDa, 29 kDa, and 20 kDa,
respectively, whereas the predicted size of the unglycosylated
FLAG-tagged GP2a used in later studies is approximately 30
kDa. Each of these proteins also has several predicted Nlinked glycosylation sites as well as amino-terminal signal sequences (Fig. 1A). We had previously shown that the major
glycoprotein GP5, when expressed ectopically in transfected
cells, remained in the endoplasmic reticulum or in the cisGolgi region (1). To examine expression of the minor glycoproteins in transfected cells, plasmids encoding these glycoproteins under the control of the T7 RNA polymerase promoter
were transfected into BHK-21 cells that had been infected with
vTF7-3, which expresses the T7 RNA polymerase. Expression
of these proteins could be readily detected (Fig. 1B) by radiolabeling and immunoprecipitation with monospecific poly-

clonal antibodies prepared against peptides containing immunodominant epitopes (11) from each of these glycoproteins.
The molecular masses of the fully mature glycoproteins (identified by white dots on the left sides of the lanes) were estimated to be approximately 32 kDa, 42 kDa, and 29 kDa,
respectively, for the GP2a, GP3, and GP4 proteins. Although
the major species of GP3 and GP4 corresponded to the fully
glycosylated and mature forms of the proteins (white dots in
lanes 4 and 6), the fully glycosylated GP2a (white dot in lane 2)
represented only a small fraction, while a smaller GP2a was
detected as the major protein species (top black dot in lane 2).
The electrophoretic mobility of this protein appeared to be
consistent with GP2a lacking glycans at one of the sites, and it
may represent a partially glycosylated form of the protein. In
addition, it should be noted that these proteins contain signal
sequences at the amino terminus, which appear to be cleaved
off to generate the mature proteins and therefore may be
smaller than the expected nonglycosylated proteins. Furthermore, based on the predicted size, it appears that these proteins possess anomalous mobilities in the gels. Since the predominant protein species in cells transfected with the GP2a
expression plasmid was smaller than the fully glycosylated mature GP2a protein, we examined whether incompletely glycosylated forms of GP2a and possibly other minor glycoproteins
were also synthesized in MARC-145 cells, which are normally
used for propagation of PRRSV. Additionally, since the major
species of GP2a possessed an electrophoretic mobility similar
to that of GP4 (Fig. 1B, lanes 2 and 6), we also examined the
expression of a carboxy-terminal FLAG-tagged GP2a protein
(GP2a-Fl) for use in later studies. Our results revealed that the
predominant protein in MARC-145 cells transfected with
GP2a-Fl-encoding plasmid also corresponded to the partially
glycosylated form of the protein (Fig. 1C), as observed earlier
in BHK-21 cells. Furthermore, the GP2a-Fl-tagged protein
could be readily distinguished from the GP4 protein based on
the mobility in the gel, a property that we have used in our
protein interaction studies reported below. Interestingly, in
MARC-145 cells, these three proteins produced a ladder-like
pattern (Fig. 1C, lanes 2, 4, and 6), indicating that the proteins
were also incompletely glycosylated in these cells. However,
the fully mature glycoproteins (white dots in Fig. 1C, lanes 2, 4,
and 6), with mobilities similar to those observed in BHK-21
cells, were readily detected in each case. Ladder-like patterns
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FIG. 1. Expression of individual minor envelope glycoproteins of PRRSV in transfected cells. (A) Schematic representation of GP2a, GP3, and
GP4 proteins, with their sizes in amino acids shown. Potential N-linked glycosylation sites (with residue number and letter Y above of the
rectangular boxes), predicted signal sequences (SS), and transmembrane regions (TM) are shown. The amino (N) and carboxy (C) termini are
identified. (B) BHK-21 cells were infected with vTF7-3 and subsequently mock transfected or transfected with plasmids encoding individual
envelope glycoproteins as shown above the lanes. The cells were radiolabeled with 35S protein labeling mix as described in Materials and Methods,
cell extracts were prepared and immunoprecipitated with monospecific polyclonal antibodies as shown below the lanes, and the proteins were
detected by SDS-10% PAGE and fluorography. The fully glycosylated proteins are identified by white dots, whereas the partially glycosylated forms
of the proteins are identified by black dots, on the left sides of the lanes. Relative mobilities of molecular mass markers in kilodaltons (kDa) are
shown on the right. (C) Expression of the GPs in MARC-145 cells. The experiment was done as described for panel B, but the plasmid encoding
GP2a with a FLAG tag was used in place of GP2a and the fusion protein was detected with anti-FLAG antibody. The full-length mature GPs are
identified with white dots in lanes 2, 4, and 6, whereas the partially glycosylated forms of the proteins are identified by black dots in the lanes.
Relative mobilities of molecular mass markers in kDa are shown on the right. (D) Endo H sensitivity of the GPs. The proteins expressed in BHK-21
cells as described above were recovered by immunoprecipitation, treated without (⫺) or with (⫹) endo H, and detected by electrophoresis as
described above. Mock-transfected cells immunoprecipitated with the antibodies and treated without endo H are shown in lanes 1, 4, and 7. White
dots show the fully glycosylated proteins, and black dots show the protein species generated by the enzyme treatment. The protein band identified
by an asterisk is most likely the signal-cleaved deglycosylated form of GP2a. Relative mobilities of molecular mass markers in kDa are shown on
the right.

of the glycoproteins were also seen in MARC-145 cells infected with PRRSV FL-12 (data not shown). It is possible that
the ladder-like pattern of the viral glycoproteins may represent
various degraded forms of the proteins. However, our observation that single and multiple N-linked glycosylation mutant
proteins comigrate with the protein bands seen in the ladderlike pattern (data to be reported elsewhere) and the fact that
endo H digestion (Fig. 1D) has resulted in detection of single
species of these proteins (except for GP2a, for which the signal-cleaved form of the protein is also detected) argue against
the possibility that the ladder-like pattern represents degraded
proteins.
The intracellular localization of the minor glycoproteins in
BHK-21 cells was further studied by examining their sensitivity
to endo H digestion and also by confocal microscopy. All of the
fully and partially glycosylated proteins in BHK-21 cells were
found to contain only high-mannose-type glycans, as they were
sensitive to digestion by endo H, yielding species that corresponded to the protein backbones only (Fig. 1D). It should be
noted that a smaller protein species (identified by asterisk on
the right of lane 3) was also detected. This protein is most
likely the signal-cleaved GP2a without glycans. Immunofluorescent staining of cells expressing the individual glycoproteins
with monospecific antibodies also showed that most of the
minor glycoproteins were localized in the cytoplasm in associ-

ation with the ER (data not shown). Similar results were also
obtained in MARC-145 cells. Overall, our results show that the
minor glycoproteins (GP2a, GP3, and GP4) synthesized in
transfected cells are localized in the ER, similar to what was
previously described for the major envelope protein GP5
(1, 53).
GP5 protein interacts strongly with GP4 protein of PRRSV.
To examine whether the envelope glycoproteins interact with
each other, we cotransfected BHK-21 cells with two plasmids
at a time encoding GP2a-Fl, GP3, GP4, or GP5. Approximately 16 h after transfection, the cells were radiolabeled and
the cell extracts were examined for protein interactions by
co-IP assays using a monospecific antibody against one of the
proteins. The results (Fig. 2A) show that the GP2a polyclonal
antibody was able to coimmunoprecipitate GP3 (lane 6) or
GP4 (lane 7) protein when they were expressed together. Since
the GP2a antibody did not immunoprecipitate GP3 (lane 3) or
GP4 (lane 4) protein when these proteins were expressed alone
in transfected cells, coimmunoprecipitation of GP3 or GP4 by
GP2a antibody in cotransfected cells indicates that GP2a interacts with both of these proteins. No detectable level of
interaction between GP2a and GP5 was observed (lane 8)
under similar conditions in repeat experiments. Similarly, by
the use of anti-GP3 polyclonal antibody, GP2a (Fig. 2B, lane 9)
and GP4 (lane 10) proteins could be coimmunoprecipitated
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FIG. 3. Interaction of GP5 with GP4 is necessary for multiprotein
complex formation. BHK-21 cells were infected with vTF7-3 and subsequently mock transfected (lane 1) or transfected with individual or
combinations of plasmids encoding various GPs as shown below each
lane. Cells were radiolabeled as described in Materials and Methods
and immunoprecipitated with antibodies as shown below the lanes.
The proteins were detected by SDS-12% PAGE and fluorography.
Various GPs are identified on the right. The fully glycosylated GPs are
identified with white dots on the left side of the lanes. GP2a (1N), the
monoglycosylated form of GP2a, is identified with black dots on the
left sides of the lanes. Relative mobilities of molecular mass markers in
kDa are shown on the left.

FIG. 2. Interaction of PRRSV GPs. (A) Examination of GP interactions using GP2a antibody. BHK-21 cells were infected with vTF7-3
virus and mock transfected (lane 1) or transfected with plasmids encoding the GPs as shown below the panel. ⫺ and ⫹ indicate transfection without or with the plasmid shown on the left. At 16 h posttransfection, the cells were radiolabeled with 35S protein labeling mix as
described in Materials and Methods, cell extracts were prepared and
immunoprecipitated with monospecific polyclonal antibodies as shown
below the lanes, and the proteins were detected by SDS-12% PAGE
and fluorography. The full-length mature GPs are identified with white
dots, whereas the partially glycosylated forms of the proteins are identified by black dots, on the left sides of the lanes. Relative mobilities of
molecular mass markers in kDa are shown on the right. (B) Examination of GP interactions using anti-GP3 antibody. The experiment was
performed as described for panel A but using anti-GP3 antibody.
(C) Examination of GP interactions using anti-GP5 antibody. The
experiment was performed as described for panel A but using anti-GP5
antibody. Relative mobilities of molecular mass markers in kDa are
shown on the right.

with GP3 in cotransfected cells, suggesting that GP3 interacts
with GP2a and GP4. Interaction between GP3 and GP5 was
not observed (lane 11) under these conditions. By the use of
monospecific anti-GP5 antibody, GP4 protein could be efficiently immunoprecipitated from cells cotransfected with plasmids encoding the GP4 and GP5 proteins (Fig. 2C, lane 11),

indicating strong interaction between these two proteins. GP2a
protein could be consistently detected at low levels when coexpressed with GP5 and immunoprecipitated with anti-GP5
antibody (lane 9). However, undetectable to very low levels of
GP3 protein could be seen in some but not all experiments
when GP3 was coexpressed with GP5 and immunoprecipitated
with anti-GP5 antibody (lane 10). Similar results were also
obtained using the anti-GP4 polyclonal antibody (data not
shown). Overall, the results from these co-IP studies suggest
that GP2a protein interacts with the GP3, GP4, and GP5
proteins; GP3 interacts with GP2a and GP4 but not with
GP5; GP4 also interacts with all the three glycoproteins; and
GP5 interacts with the GP4 and GP2a proteins. Although
the extent of interaction between the GPs is difficult to
estimate from the co-IP studies, it is clear that the interaction of GP4 with GP5 appears to be much stronger than the
interactions between the other GPs.
GP4 mediates interactions resulting in detection of a multiprotein complex. To further examine whether multiprotein
glycoprotein complexes can be detected by co-IP assay, we
transiently expressed multiple glycoproteins of PRRSV in
BHK-21 cells and attempted to pull down all the interacting
glycoproteins using one monospecific antibody by co-IP. We
chose to use GP3 antibody in this study, as the use of this
antibody in BHK-21 cell extracts resulted in fewer background
bands (Fig. 1B). We observed that the GP3 antibody was not
able to pull down GP5 protein when both of these proteins
were coexpressed (Fig. 3, lane 6), confirming the results obtained previously. Furthermore, this antibody was able to pull
down small amounts of GP2a protein but not GP5 protein
when these three proteins were coexpressed (lane 7), indicat-
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FIG. 4. Expression and functional analysis of CD163. (A) Expression of CD163 in transfected cells. BHK-21 cells were infected with vTF7-3
and transfected with pcDNA3.1 (E. Vector, lane 1) or CD163 cDNA containing clones (no. 1, 2, 3, and 4 [lanes 2 to 5, respectively]). Cells were
radiolabeled for 4 h at 16 h posttransfection, and the radiolabeled proteins were analyzed by immunoprecipitation with porcine anti-CD163
monoclonal antibody, resolved by SDS-10% PAGE, and detected by fluorography. Mobilities of full-length CD163 and its truncated form
(CD163⌬TM) are shown on the right. Relative mobilities of molecular mass markers in kDa are shown on the left. (B) Susceptibility of BHK-21
cells expressing CD163 encoded in the clones to PRRSV infection. Cells were transfected with the plasmid clones as shown (EV, empty vector
control), and expression of CD163 was driven by the CMV promoter in pcDNA3.1 vector. At 48 h after transfection, cells were infected with
PRRSV and expression of N protein was examined using the monoclonal antibody SDOW17 and secondary antibody conjugated to Alexa-488.
(C) Immunofluorescent staining of BHK-21 cells transfected with empty vector (panels a and b), full-length CD163 receptor encoding clone 2
(panels c and d), or the CD163⌬TM-encoding clone (panels e and f). Cell surface or cytoplasmic staining was performed with CD163 monoclonal
antibody and Alexa-488 conjugated secondary antibody.

ing that GP3 interaction with GP2a is not sufficient to pull
down GP5 protein in co-IP assay. However, when the GP3,
GP4, and GP5 proteins were coexpressed, all the three proteins could be specifically immunoprecipitated with anti-GP3
antibody (lane 8), indicating that GP4 protein was important
for generation of this tripartite glycoprotein complex. Additionally, when all the four glycoproteins were coexpressed and
immunoprecipitation was carried out with GP3 antibody, all
four proteins could be detected (lane 9). The results suggest
that GP4 most likely mediates the interactions among PRRSV
glycoproteins to generate the multiprotein glycoprotein complex.
Cloning, expression, and functionality of porcine CD163,
the cellular receptor for PRRSV. It was previously reported
that the expression of porcine CD163 in a nonpermissive cell
confers susceptibility to PRRSV infection (5). A recent study
(48) suggested that CD163 acts internally to uncoat the virus
genome and that expression of both CD163 and sialoadhesin is
required for efficient infection by PRRSV. However, in the
same study (48), it was also shown that expression of CD163
alone in BHK-21 cells, which are otherwise nonpermissive to
PRRSV infection, led to productive infection, indicating that
CD163 alone is sufficient to establish a productive replicative
cycle of the virus. Therefore, PRRSV must bind to cells expressing CD163 to initiate the viral replication process. To
determine which of the PRRSV envelope glycoproteins inter-

act with CD163, we first cloned in pcDNA3.1(⫹) vector the
full-length cDNA of CD163 from porcine alveolar macrophage
(PAM) cells by RT-PCR amplification of total RNA from the
cells using CD163-specific primers (Table 1). Four clones were
used to examine the expression of the encoded protein by
transfection, radiolabeling, and immunoprecipitation with porcine anti-CD163 antibody. We observed that three of the
clones expressed proteins (Fig. 4A, lanes 3 to 5) that could be
specifically immunoprecipitated with anti-CD163 antibody and
possessed an electrophoretic mobility (⬃130 kDa) corresponding to the full-length CD163 (5). A smaller protein product of
⬃100 kDa encoded in another clone was also detected by the
CD163 antibody (Fig. 4A, lane 2). Sequence analysis of
the clones showed that CD163 in the clone that produced the
smaller protein contained a premature termination codon at aa
position 893, resulting in a truncated protein of 892 aa corresponding to the observed molecular mass. This truncated protein lacks the carboxy-terminal cytoplasmic domain, the transmembrane (TM) domain, and the ninth repeat unit of the
scavenger receptor cysteine-rich (SRCR) protein domain (33).
We have termed this truncated protein CD163⌬TM. The
CD163 cDNAs in the other clones contained full-length sequences of 1,115 amino acids with greater than 99% sequence
identity with the reported sequence of the porcine CD163
(5, 40).
To determine if the cloned CD163 confers susceptibility to
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FIG. 5. Interaction of CD163 with PRRSV GPs. (A) BHK-21 cells were infected with vTF7-3 and transfected with various GPs alone or in
combination with CD163 (clone 2). The cells were radiolabeled, and the proteins were immunoprecipitated with antibodies as shown below the
lanes. Immunoprecipitated proteins were detected by SDS-10% PAGE and fluorography. Mobilities of molecular mass marker proteins in kDa are
shown on the right. CD163 and the fully glycosylated viral GPs are identified on the left. Fully glycosylated GPs are identified with white dots in
the fluorograms on the left side of each lane. The monoglycosylated GP2a is identified with black dots on the left side in lanes 3 and 11. (B).
Interaction of GP2a and GP4 with CD163⌬TM. The experiment was performed as described for panel A using the clone encoding the CD163⌬TM
protein.

PRRSV infection, we transfected the plasmids into BHK-21
cells, which are nonpermissive to PRRSV infection. Subsequently, at about 48 h posttransfection the cells were infected
with PRRSV. Synthesis of N protein, which is indicative of
PRRSV entry, transcription, and replication was examined in
these cells by immunofluorescent staining of the cells at 48 h
postinfection with anti-N monoclonal antibody SDOW17 (38).
Synthesis of the N protein was readily detected in the cells
transfected with clones encoding the full-length CD163 (Fig.
4B), indicating that the CD163 encoded in these clones conferred susceptibility to PRRSV infection. The N protein was
not detected in cells transfected with the clone encoding
CD163⌬TM, suggesting that this truncated protein is nonfunctional in conferring PRRSV susceptibility to the cells. The
inability of CD163⌬TM to confer PRRSV susceptibility to the
cells is not due to low levels of expression of the protein, since
under similar transfection conditions, CD163⌬TM is detected
at least at levels similar to or greater than that of the full-length
protein (Fig. 4A). The results indicate that the carboxy-terminal 223 amino acids of CD163 are required for the function of
the protein in conferring PRRSV susceptibility. It is possible
that CD163⌬TM may have defective cellular localization or
improper folding, leading to loss of its function.
Immunofluorescence microscopic examination of cells transfected with one of the full-length CD163 clones showed that
CD163 protein was localized on the plasma membrane (Fig.
4C, panel c) as well as in the cytoplasm (Fig. 4C, panel d). Cells
transfected with the clone encoding CD163⌬TM showed no
surface expression of the protein (Fig. 4C, panel e), although
the protein was expressed in the cytoplasm (Fig. 4C, panel f),
indicating that CD163⌬TM is defective in plasma membrane
localization. Empty vector-transfected cells did not exhibit any
immunofluorescent staining on the plasma membrane or in the
cytoplasm (Fig. 4C, panels a and b).
The GP2a and GP4 proteins of PRRSV interact with the
porcine CD163 receptor. We next wanted to examine which of

the PRRSV envelope glycoproteins interact with the receptor
CD163. To perform these studies, the CD163 along with each
of the four envelope glycoproteins was coexpressed in transfected cells, and interactions were examined by co-IP with
porcine CD163 monoclonal antibody. This antibody did not
immunoprecipitate the individual glycoproteins when these
glycoproteins were expressed alone (Fig. 5A, lanes 7 to 10),
demonstrating that the antibody does not immunoprecipitate
the proteins nonspecifically. However, when the individual glycoproteins were coexpressed with CD163, GP2a and GP4 proteins could be specifically immunoprecipitated with antiCD163 antibody (lanes 11 and 13) in multiple repeat
experiments. Interestingly, both the mature GP2a and partially
glycosylated GP2a proteins (identified by white and black dots,
respectively, in lane 11) could be immunoprecipitated with the
CD163 antibody (lane 11), indicating that both forms of GP2a
interact with CD163. The use of GP-specific antibodies also
showed that CD163 protein could be immunoprecipitated with
anti-GP2a or anti-GP4 antibodies (data not shown). The GP3
and GP5 proteins could not be detected by immunoprecipitation with anti-CD163 antibody (lanes 12 and 14) from cotransfected cells. These results suggest that the GP3 and GP5 proteins do not interact with the CD163 or that their interactions
cannot be detected under conditions in which interactions with
GP2a and GP4 could be readily detected.
Further, we performed a co-IP assay in which CD163⌬TM
was coexpressed with the viral GPs (Fig. 5B). By using the
CD163 monoclonal antibody, we were able to pull down GP2a
or GP4 protein, indicating that the 223 amino acids from the
carboxy terminus of CD163 that are missing in CD163⌬TM are
not required for its interaction with the GP2a or GP4 protein.
DISCUSSION
PRRSV contains one major glycoprotein (GP5) and three
minor glycoproteins (GP2a, GP3, and GP4) on the virion en-
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velope. All of these glycoproteins are required for generation
of infectious virions, indicating that they play critical roles in
virion assembly and/or interactions with the cell surface receptor for virus entry and/or uncoating. Previous studies have
reported that GP2a, GP3, GP4, and the unglycosylated envelope protein 2b form a multiprotein complex in cells expressing
these proteins (53). In this study, we have examined the interactions of the envelope glycoproteins among themselves as
well as the interactions of these proteins with the cell surface
receptor, CD163. Overall, our studies lead us to conclude that
(i) the GP4 and GP2a proteins interact with the other GPs; (ii)
GP4 mediates the formation of the multiprotein complex between the minor GPs and the major envelope GP, GP5; and
(iii) GP4 along with GP2a interact with CD163. These studies
for the first time show that the GP4 protein is the key glycoprotein of PRRSV that is responsible for formation of the
multiprotein complex and, along with GP2a, may serve as the
viral attachment protein, allowing virus binding to the cell
surface receptor during infection.
Expression of the individual minor glycoproteins in transfected cells resulted in detection of these proteins by the corresponding monospecific antibodies. Several partially glycosylated forms of the proteins could be readily detected by the
antibodies. Particularly striking was the detection of a ladderlike pattern of GP3 in MARC-145 cells (Fig. 1C), which most
likely corresponds to the partially glycosylated forms of the
protein. Partially glycosylated forms were also observed for the
GP2a and GP4 proteins in both BHK-21 and MARC-145 cells.
For GP2a, the size of the major species of the protein corresponds to that lacking one glycan moiety. GP2a contains two
N-glycosylation sites, at residues 178 and 184. The reason(s)
for the synthesis of predominantly a GP2a molecule with one
glycan moiety is not clear at this time. However, it is possible
that one of the N-glycosylation sites is glycosylated inefficiently
or with reduced frequency, resulting in a predominantly monoglycosylated GP2a. It has been suggested that N-glycosylation
sites are less likely to be used if they have not passed through
the oligosaccharyltransferase (OST) active site prior to translation termination (22). The estimated distance between the
peptidyl transferase site of a ribosome attached to the translocation pore on the ER membrane and the active site of OST
complex roughly corresponds to 75 amino acid residues (3, 22,
23, 51). Since cotranslational and posttranslational glycosylation on a single protein have been demonstrated (4) and such
modifications occur by distinct mammalian OST isoforms (39),
we speculate that the glycosylation site at residue 184 in GP2a
is most likely modified inefficiently and/or modified by posttranslational glycosylation. It is possible that glycan addition at
the sites in the GP3 and GP4 proteins is also inefficient and
may occur through co- and posttranslational mechanisms, resulting in ladder-like patterns of these proteins as seen in Fig.
1. We are currently examining whether the PRRSV GPs are
glycosylated through cotranslational as well as posttranslational mechanisms.
It has been previously reported for the genotype II Lelystad
virus that the envelope minor glycoproteins and 2b (or E)
protein together form a heterotetrameric complex and that this
complex formation is crucial for intracellular targeting of these
proteins from the ER through the Golgi complex to the plasma
membrane (53). Our studies not only confirm these observa-
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tions but also show that the major envelope glycoprotein GP5
interacts with GP4 strongly. Although direct interaction between GP3 and GP5 could not be demonstrated, a multiprotein complex comprising all four envelope glycoproteins could
be readily detected by immunoprecipitation with anti-GP3 antibody (Fig. 3). Our studies suggest that GP4 mediates the
formation of the large multiprotein complex between the minor and the major envelope proteins of PRRSV. In cells expressing GP5 alone or in the presence of M protein, GP5 does
not acquire endo-H resistance even after 4 h of synthesis (1),
but in virus-infected cells or in the extracellular virions, the
GP5 becomes endo H resistant (1). These results indicate that
the multiprotein complex generated by the interactions of the
envelope proteins may be critical for the transport of these
proteins from the ER to the Golgi complex and finally to the
plasma membrane for incorporation into virus particles, consistent with previous findings that the minor envelope glycoproteins of Lelystad virus form a multimeric complex for their
transport to the plasma membrane (53).
Although multiprotein complexes can be detected in transfected cells, the molar ratio of the proteins in such complexes
is unknown. Since the GP5 and M proteins are the major
envelope proteins, they are likely distributed uniformly
throughout the virion envelope. Recent cryo-electron tomographic studies (44) reveal that PRRSV particles display
mostly smooth envelope outlines, for which the authors suggest
that the small ectodomains of GP5 and M proteins are possibly
not large enough to be detected as visible spikes on the virion
envelope. On the other hand, the authors also detected a few
features protruding from the virion envelope, which most likely
correspond to the large multimeric complexes made from the
bulkier but less abundant minor envelope glycoproteins such as
GP2a (44). We reason that the protruding features seen on the
PRRSV virion envelope represent the multimeric complexes
of the minor envelope glycoproteins with or without the GP5
and M proteins, and these are likely to be directly involved in
interactions with the cell surface receptor during PRRSV infection.
The data presented here support the contention that the
multimeric complexes of the minor glycoproteins with or without the M and GP5 proteins are involved in direct interaction
with the cell surface receptor. Since the GP5 and M proteins
are present in abundant amounts on the virion envelope, these
two proteins were considered to play a major role in receptor
interaction. However, this contention was challenged by the
results from the studies using chimeric viruses (17, 50), which
suggested that the GP5 and M proteins do not play a role in
receptor interaction. Our studies show that only the GP2a and
GP4 proteins interact with CD163. It appears that GP4 is a
critical viral envelope protein that not only mediates interactions with other GPs on the virion envelope but also, along
with GP2a, mediates interactions with CD163 for virus entry.
Since the minor envelope proteins are not required for particle
formation (53) and there are only a few large multimeric glycoprotein complexes present on the virion envelope (44), we
suggest that the major function of the minor glycoprotein complex on the virion envelope is to interact specifically with the
cell surface receptor for virus entry. On the other hand, the
GP5 and M heterodimeric complexes, which are present in
large amounts and are uniformly distributed throughout the
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2b and M in the formation of this complex or interaction with
CD163 has not been examined in the current study, several of
these interactions have already been confirmed. Further studies are being conducted to test this preliminary model of GPCD163 interaction.
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shown as a structure with an extracellular region having repeating units
(corresponding to the nine SRCR domains) projecting from the
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lines in the schematic represent the regions of the proteins that are
masked by GP2a.
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